BMND8
MCID: BNM022
MIFTS: 45

Bone Mineral Density Quantitative Trait Locus 8 (BMND8)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 8

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 8:

Name: Bone Mineral Density Quantitative Trait Locus 8 57
Osteoporosis, Susceptibility to 57 6
Osteoporosis 57 71
Bmnd8 57

Classifications:



External Ids:

OMIM® 57 611739
UMLS 71 C0029456

Summaries for Bone Mineral Density Quantitative Trait Locus 8

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 8, also known as osteoporosis, susceptibility to, is related to bone mineral density quantitative trait locus 15 and osteoporosis, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Bone Mineral Density Quantitative Trait Locus 8 is BMND8 (Bone Mineral Density Quantiative Trait Locus 8). The drugs Pioglitazone and Linagliptin have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and bone marrow.

Wikipedia : 74 Bone mineral density quantitative trait locus 8 is a protein that in humans is encoded by the BMND8... more...

More information from OMIM: 611739

Related Diseases for Bone Mineral Density Quantitative Trait Locus 8

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 8 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1087)
# Related Disease Score Top Affiliating Genes
1 bone mineral density quantitative trait locus 15 32.1 PDLIM4 CALCR
2 osteoporosis 31.8 PDLIM4 CALCR BMND8
3 osteoporosis, juvenile 11.8
4 osteoporosis-pseudoglioma syndrome 11.7
5 hajdu-cheney syndrome 11.5
6 glucocorticoid-induced osteoporosis 11.5
7 nephrolithiasis/osteoporosis, hypophosphatemic, 1 11.5
8 nephrolithiasis/osteoporosis, hypophosphatemic, 2 11.5
9 juvenile primary osteoporosis 11.5
10 hypophosphatemic nephrolithiasis/osteoporosis 11.3
11 osteoporosis and oculocutaneous hypopigmentation syndrome 11.3
12 bone mineral density quantitative trait locus 16 11.3
13 bone mineral density quantitative trait locus 18 11.2
14 bone disease 11.2
15 bone resorption disease 11.2
16 rickets 11.1
17 premature menopause 11.1
18 werner syndrome 11.1
19 syndromic x-linked intellectual disability snyder type 11.1
20 multicentric osteolysis, nodulosis, and arthropathy 11.1
21 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 11.1
22 hyperparathyroidism 11.1
23 aromatase deficiency 11.1
24 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 11.0
25 winchester syndrome 11.0
26 bone mineral density quantitative trait locus 12 11.0
27 lysinuric protein intolerance 11.0
28 geroderma osteodysplasticum 11.0
29 epiphyseal dysplasia, multiple, with early-onset diabetes mellitus 11.0
30 mucolipidosis iii alpha/beta 11.0
31 nestor-guillermo progeria syndrome 11.0
32 ehlers-danlos syndrome, classic-like, 2 11.0
33 hypogonadotropic hypogonadism 11.0
34 hyperthyroidism 11.0
35 anorexia nervosa 10.9
36 cerebrotendinous xanthomatosis 10.9
37 cholangitis, primary sclerosing 10.9
38 bone mineral density quantitative trait locus 3 10.9
39 celiac disease 1 10.9
40 spondyloocular syndrome 10.9
41 cleidocranial dysplasia 10.9
42 mental retardation, x-linked, syndromic, snyder-robinson type 10.9
43 acth-secreting pituitary adenoma 10.9
44 cutis laxa osteoporosis 10.9
45 systemic mastocytosis 10.9
46 hyperparathyroidism 1 10.9
47 dyskeratosis congenita, autosomal recessive 1 10.9
48 hyaline fibromatosis syndrome 10.9
49 mucolipidosis iii gamma 10.9
50 prader-willi habitus, osteopenia, and camptodactyly 10.9

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 8:



Diseases related to Bone Mineral Density Quantitative Trait Locus 8

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 8

Clinical features from OMIM®:

611739 (Updated 05-Mar-2021)

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 8:


tremor, back pain, angina pectoris, sciatica, equilibration disorder, muscle cramp, pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 8

Drugs for Bone Mineral Density Quantitative Trait Locus 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 384)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
2
Linagliptin Approved Phase 4 668270-12-0 10096344
3
Atorvastatin Approved Phase 4 134523-00-5 60823
4
Bazedoxifene Approved, Investigational Phase 4 198481-32-2
5
Racepinephrine Approved Phase 4 329-65-7 838
6
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
7
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
8
Etidronic acid Approved Phase 4 2809-21-4, 7414-83-7 3305
9
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
10
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
11
Ribavirin Approved Phase 4 36791-04-5 37542
12
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
13
Gliclazide Approved Phase 4 21187-98-4 3475
14
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
15
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
16
Demeclocycline Approved Phase 4 127-33-3 5311063
17
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
18
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
19
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
20
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
21
Lactitol Approved, Investigational Phase 4 585-86-4 157355
22
Tibolone Approved, Investigational Phase 4 5630-53-5
23
Liraglutide Approved Phase 4 204656-20-2 44147092
24
Cinacalcet Approved Phase 4 226256-56-0 156419
25
Sodium citrate Approved, Investigational Phase 4 68-04-2
26
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
27
tannic acid Approved Phase 4 1401-55-4
28
Morphine Approved, Investigational Phase 4 57-27-2 5288826
29
Ibuprofen Approved Phase 4 15687-27-1 3672
30
Cetrorelix Approved, Investigational Phase 4 120287-85-6 16129715 25074887
31
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
32
Acetaminophen Approved Phase 4 103-90-2 1983
33
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
34
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
35
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
36 Abaloparatide Approved, Investigational Phase 4 247062-33-5
37
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
38
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
39
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
40
Pravastatin Approved Phase 4 81093-37-0 54687
41
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
42
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
43
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
44
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 4 53-43-0 5881
45
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
46
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
47 Progestins Phase 4
48 HIV Protease Inhibitors Phase 4
49
protease inhibitors Phase 4
50 Phytoestrogens Phase 4

Interventional clinical trials:

(show top 50) (show all 1336)
# Name Status NCT ID Phase Drugs
1 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
2 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
3 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
4 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
5 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
6 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
7 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
8 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
9 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
10 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
11 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
12 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
13 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
14 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
15 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
16 Effect of Periodontal Therapy and Bisphosphonates on Gingival Crevicular Fluid Levels of Nuclear Factor- κb Ligand (RANKL) and Osteoprotegerin in Postmenopausal Osteoporosis: Results of a 12-Month Study Completed NCT02808988 Phase 4
17 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
18 Influence of Alfacalcidol on Falls in Elderly Postmenopausal, Alendronate-Treated, Osteopenic/Osteoporotic Women With High Risk of Falls Completed NCT00168909 Phase 4 alfacalcidol;placebo
19 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
20 Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures Completed NCT01383616 Phase 4
21 OSTPRE-FPS Prevention of Fractures and Falls in Postmenopausal Women With Calcium and Vitamin-D Supplementation - a Randomised Study Completed NCT00592917 Phase 4
22 The Change of Bone Markers After Low Dose Alendronate in Postmenopausal Women Completed NCT00460057 Phase 4 Alendronate
23 Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy: a Randomized Double-blind Placebo-controlled Study Completed NCT00371956 Phase 4 raloxifene;placebo
24 The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients - A Prospective, Randomised, Controlled Clinical Trial Completed NCT00114556 Phase 4 zoledronic acid
25 A Multi Centre, Randomised, Open Label, Cross-over Study to Evaluate the Percentage of False Negative Osteoporosis Diagnosis's Using the Standard Case-finding Procedure as Described by the Dutch Institute for Healthcare (CBO) and to Determine the Preference of Adult Osteoporosis Patients Between Once Monthly Dosing of Ibandronate (150 mg) and Once Weekly Dosing of Alendronate (70 mg) Completed NCT00327990 Phase 4 Ibandronate;Alendronate
26 Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 Completed NCT00948220 Phase 4 peginterferon alfa-2a and ribavirin
27 Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism Completed NCT02417389 Phase 4 cinacalcet;Alendronate
28 Fracture (FX) Improvement With Teriparatide: FiX-IT Study Completed NCT01705587 Phase 4 teriparatide
29 Antiepileptic Drugs and Osteoporotic Prevention Trial Completed NCT00869622 Phase 4 Risedronate;Placebo + Calcium and Vitamin D
30 Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability.A Comparison Between Vildagliptin and Gliclazide MR Completed NCT01679899 Phase 4 Vildagliptin;Gliclazide MR
31 Skeletal Histomorphometry in Patients on Teriparatide or Zoledronic Acid Therapy Completed NCT00927186 Phase 4 Teriparatide;Zoledronic Acid
32 Switch From Tenofovir to Raltegravir for Low Bone Mineral Density Completed NCT00939874 Phase 4 Raltegravir
33 High Dosage Vitamin D in the Treatment of Osteoporosis in Postmenopausal Women Completed NCT00491920 Phase 4 cholecalciferol (Vitamin D3);placebo
34 The Effect of Zoledronic Acid Infusion in the Bone Loss Observed Following Denosumab Discontinuation in Postmenopausal Women With Low Bone Mass Completed NCT02499237 Phase 4 Denosumab;Zoledronic acid
35 A 6-Month, Randomized, Open-Label, Active-Comparator Controlled, Parallel-Group Study With a 6-Month Extension to Evaluate the Safety and Efficacy of Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combination Tablets Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China Completed NCT01350934 Phase 4 alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus);Calcitriol
36 Denosumab and Teriparatide Study (DATA-HD and DATA-EX) Completed NCT02176382 Phase 4 denosumab;teriparatide;Zoledronic acid
37 Pearlium®/Effecti-Cal®, a Novel Formulation of Calcium, Vitamin D and Minerals for Prevention of Postmenopausal Bone Loss Completed NCT04609189 Phase 4 Pearlium/EffectiCal;Calcium carbonate/vitamin D3
38 Open Label, Parallel Group, Multicenter Study of Two Intravenous (IV) Ibandronate Dose Regimens (2 mg Every 2 Months and 3 mg Every 3 Months) in Women With Postmenopausal Osteoporosis Who Completed Trial BM16550 Completed NCT00551174 Phase 4 ibandronate [Bonviva/Boniva];ibandronate [Bonviva/Boniva]
39 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]
40 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Study pn Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Risedronate Sodium (Actonel) in Administered 35mg Once a Week or 5mg Once Daily Completed NCT00453492 Phase 4 risedronate sodium
41 A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 35-mg Risedronate Administered Once a Week in the Prevention of Osteoporosis in Postmenopausal Women Completed NCT00402441 Phase 4 Risedronate (HMR4003)
42 Randomized, Open-label, Multi-center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once Monthly Ibandronate and Once Weekly Risedronate. A Six Month, Two-sequence and Two-period Crossover Study. Completed NCT00377234 Phase 4 Risedronate;ibandronate [Bonviva/Boniva]
43 A Randomized Placebo Controlled Double Blind Investigation of the Effects of Potassium Citrate on Bone Metabolism in Postmenopausal Osteopenia Completed NCT00357331 Phase 4 potassium citrate
44 Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis Completed NCT00035256 Phase 4 teriparatide;raloxifene HCl;placebo
45 An Open-Label, Multi-Center Study to Determine Level of Adherence to Monthly Oral or Every Three Month Intravenous Ibandronate Treatment in Post-Menopausal Women With Osteoporosis or Osteopenia, Who Are GI Intolerant of Daily or Weekly Alendronate or Risendronate Completed NCT02598453 Phase 4 Ibandronate
46 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
47 A Prospective, Randomized, Open-label, Active-controlled Study to Evaluate the Efficacy and Safety of Fosamax Plus D in Postmenopausal Osteoporotic Women Completed NCT00729651 Phase 4 alendronate sodium (+) cholecalciferol;Comparator: Alendronate sodium (Fosamax)
48 A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis Completed NCT00303485 Phase 4 Placebo;Vitamin D and calcium supplementation;ibandronate [Bonviva/Boniva]
49 A Randomized Double-blind Study to Evaluate the Safety and Efficacy of Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates Completed NCT01732770 Phase 4 Zoledronic Acid;Placebo to Denosumab;Placebo to Zoledronic Acid
50 Multi-centre, Randomized, Open Label Trial to Evaluate the Effects of Switching to Bazedoxifene in Comparison With Switching to Calcium and Vitamin D in Postmenopausal Women Previously Treated With Bisphosphonates Completed NCT02090400 Phase 4 Bazedoxifene;Calcium/Vit D

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 8

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
SODIUM FLUORIDE PWDR

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 8

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 8

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 8:

40
Bone, Prostate, Bone Marrow, Breast, Liver, Spinal Cord, Kidney

Publications for Bone Mineral Density Quantitative Trait Locus 8

Articles related to Bone Mineral Density Quantitative Trait Locus 8:

(show top 50) (show all 30004)
# Title Authors PMID Year
1
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. 6 61
19920351 2009
2
Linkage to chromosome 11p12 in two Maltese families with a highly penetrant form of osteoporosis. 61 57
17377523 2007
3
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 6
12908099 2003
4
Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. 6
9817931 1998
5
Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. 6
9571205 1998
6
Allelic variants of human calcitonin receptor in the Japanese population. 6
9003491 1997
7
Ficus deltoidea promotes bone formation in streptozotocin-induced diabetic rats. 61
33399485 2021
8
Severe injury-induced osteoporosis and skeletal muscle mineralization: Are these related complications? 61
33490313 2021
9
Effect of ErhBMP-2-loaded β-tricalcium phosphate on ulna defects in the osteoporosis rabbit model. 61
33364265 2021
10
Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab. 61
33506078 2021
11
Effect of Education on Preventive Behaviors of Osteoporosis in Adolescents: A Systematic Review and Meta-Analysis. 61
32586215 2021
12
Anti-perimenopausal osteoporosis effects of Erzhi formula via regulation of bone resorption through osteoclast differentiation: A network pharmacology-integrated experimental study. 61
33444724 2021
13
New mandibular indices in cone beam computed tomography to identify low bone mineral density in postmenopausal women. 61
32843313 2021
14
Shuxuetong injection simultaneously ameliorates dexamethasone-driven vascular calcification and osteoporosis. 61
33488806 2021
15
Bone health assessment via digital wrist tomosynthesis in the mammography setting. 61
33321264 2021
16
Comprehensive evaluation of the combined extracts of Epimedii Folium and Ligustri Lucidi Fructus for PMOP in ovariectomized rats based on MLP-ANN methods. 61
33176184 2021
17
Application study of three-dimensional printed navigation template between traditional and novel cortical bone trajectory on osteoporosis lumbar spine. 61
33581788 2021
18
Chronic hepatitis, osteoporosis, and men: under-recognised and underdiagnosed. 61
33607040 2021
19
The treatment gap: The missed opportunities for osteoporosis therapy. 61
33359889 2021
20
Opportunistic screening for osteoporosis and osteopenia by routine computed tomography scan: A heterogeneous, multiethnic, middle-eastern population validation study. 61
33545629 2021
21
A role for the MEGF6 gene in predisposition to osteoporosis. 61
33026655 2021
22
The gap between women's needs when diagnosed with asymptomatic osteoporosis and what is provided by the healthcare system: A qualitative study. 61
30525980 2021
23
Ameliorative effects of Osteo-F, a newly developed herbal formula, on osteoporosis via activation of bone formation. 61
33212177 2021
24
QingYan formula extracts protect against postmenopausal osteoporosis in ovariectomized rat model via active ER-dependent MEK/ERK and PI3K/Akt signal pathways. 61
33264660 2021
25
Effects of monthly intravenous ibandronate on bone mineral density and microstructure in patients with primary osteoporosis after teriparatide treatment: The MONUMENT study. 61
33249321 2021
26
Isoflavone-enriched soybean leaves attenuate ovariectomy-induced osteoporosis in rats by anti-inflammatory activity. 61
32851642 2021
27
Persistence with osteoporosis treatment in patients from the Lille University Hospital Fracture Liaison Service. 61
33385615 2021
28
The effect of P2X7 on cadmium-induced osteoporosis in mice. 61
33168313 2021
29
Diet quality and a traditional dietary pattern predict lean mass in Australian women: Longitudinal data from the Geelong Osteoporosis Study. 61
33505843 2021
30
A promising biomarker of elevated galanin level in hypothalamus for osteoporosis risk in type 2 diabetes mellitus. 61
33383074 2021
31
Gender differences in the presentation, course and outcomes of primary hyperparathyroidism. 61
33541557 2021
32
The Application of PRECEDE Model on Preventing Osteoporosis in Women. 61
31434510 2021
33
Nanoceria provides antioxidant and osteogenic properties to mesoporous silica nanoparticles for osteoporosis treatment. 61
33359295 2021
34
Associations between osteoporosis and risk of periodontitis: A pooled analysis of observational studies. 61
32615008 2021
35
Diet-derived fruit and vegetable metabolites show sex-specific inverse relationships to osteoporosis status. 61
33278656 2021
36
Does Quantitative Ultrasound at the Calcaneus Predict an Osteoporosis Diagnosis in Postmenopausal Women from the Silesia Osteo Active Study? 61
33339648 2021
37
Parity, Breastfeeding, and Osteoporosis. 61
33057759 2021
38
Parity, Breastfeeding, and Osteoporosis-Authors' Response. 61
33057761 2021
39
Testosterone and Bone Health in Men: A Narrative Review. 61
33540526 2021
40
Association of some dietary ingredients, vitamin D, estrogen, and obesity polymorphic receptor genes with bone mineral density in a sample of obese Egyptian women. 61
33559788 2021
41
Persistence with Denosumab in Women at High Risk of Fracture in Bulgaria. 61
33555564 2021
42
A multiscale study of structural and compositional changes in a natural nanocomposite: Osteoporotic bone with chronic endogenous steroid excess. 61
33007528 2021
43
Analysis of mechanotransduction dynamics during combined mechanical stimulation and modulation of the extracellular-regulated kinase cascade uncovers hidden information within the signalling noise. 61
33343875 2021
44
Absorption and transport of a Mytilus edulis-derived peptide with the function of preventing osteoporosis. 61
33564802 2021
45
Evaluation of an Osteoporosis Outreach Program for Men With a Fragility Fracture and Their Physicians. 61
33273290 2021
46
Fragility of results from randomized controlled trials supporting the guidelines for the treatment of osteoporosis: a retrospective analysis. 61
33595680 2021
47
Osteosarcopenia: where osteoporosis and sarcopenia collide. 61
33276373 2021
48
Interplay between Mineral Crystallinity and Mineral Accumulation in Health and Postmenopausal Osteoporosis. 61
33582361 2021
49
Total glycosides and polysaccharides of Cistanche deserticola prevent osteoporosis by activating Wnt/β-catenin signaling pathway in SAMP6 mice. 61
33549763 2021
50
Incidence of and risk for osteonecrosis of the jaw in Korean osteoporosis patients treated with bisphosphonates: A nationwide cohort-study. 61
32956854 2021

Variations for Bone Mineral Density Quantitative Trait Locus 8

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 8:

6
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LOC113839511 NR_036055.1(MIR2861):n.33C>G SNV association 106 rs794728003 9:130548229-130548229 9:127785950-127785950
2 CALCR NM_001742.4(CALCR):c.1340T>C (p.Leu447Pro) SNV risk factor 17636 rs1801197 7:93055753-93055753 7:93426441-93426441
3 PDLIM4 RIL, -3333T-C SNV risk factor 6348

Expression for Bone Mineral Density Quantitative Trait Locus 8

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 8.

Pathways for Bone Mineral Density Quantitative Trait Locus 8

GO Terms for Bone Mineral Density Quantitative Trait Locus 8

Sources for Bone Mineral Density Quantitative Trait Locus 8

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....